Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

A pharmaceutical composition containing F1 polypeptide and/or F3 polypeptide and a use thereof are provided. The pharmaceutical composition is made into a common dosage form, such as an emulsion and an ointment, and used for treating a disease, such as a wart associated with a HPV infection, or a solid tumor associated with or not associated with the HPV infection.

This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.

This document provides methods and materials involved in treating mammals having had a hemorrhagic stroke. For example, methods and materials for administering a composition containing exogenous nucleic acid encoding a NeuroD1 polypeptide and exogenous nucleic acid encoding a Dlx2 polypeptide to a mammal having had a hemorrhagic stroke are provided.

The invention provides a method and kits for inhibiting integrin α9β1 activity comprising contacting integrin α9β1 or a binding partner of integrin α9β1 with an isolated anti-integrin α9 inhibitor, wherein the integrin α9β1 activity is inhibited. In certain aspects, the present invention provides a novel intervention by targeting integrin α9β1 with a functional blocking inhibitor (e.g., peptides or antibodies) to limit brain damage following reperfusion after ischemic stroke.

The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRPFc is enhanced in the presence of daratumumab. Specific combinations include SIRPFc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

Disclosed herein are a pharmaceutical composition comprising an integrin 21 inhibitor as an active ingredient for prevention or treatment of tissue adhesion, a method for screening a material prophylactic of or therapeutic for tissue adhesion, an anti-adhesion composition comprising the pharmaceutical composition for prevention or treatment of tissue adhesion as an active ingredient, and a method for prevention or treatment of tissue adhesion. The present disclosure can be advantageously used for preventing or treating tissue adhesion.

Methods for improving quality of life and/or increasing activity in an aging and/or chronically ill mammal via administration of a composition of egg yolk powder are provided. In some embodiments, additional agents improving quality of life and/or increasing activity in an aging and/or chronically ill mammal are administered in combination with the egg yolk powder.